Down-regulation of porin M35 in Moraxella catarrhalis by aminopenicillins and environmental factors and its potential contribution to the mechanism of resistance to aminopenicillins

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 10, 2010, Pages 2089-2096

  Jetter, Marion ^a   Spaniol, Violeta ^a   Troller, Rolf ^a   Aebi, Christoph ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Acute otitis media; Amoxicillin; Antimicrobial susceptibility; Stress response

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; MESSENGER RNA; PORIN; PORIN M35; RNA 16S; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; IRON RESTRICTION; MIDDLE EAR; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SCREENING TEST; STRESS; WESTERN BLOTTING;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; DOWN-REGULATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; PENICILLINS; PORINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, BACTERIAL; RNA, MESSENGER;

EID: 77957239592     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq312     Document Type: Article

References (74)

1. Murphy TF, Brauer AL, Grant BJ et al. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005; 172: 195-9.
2. Murphy TF, Parameswaran GI. Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis 2009; 49: 124-31.
3. Marchant CD. Spectrum of disease due to Branhamella catarrhalis in children with particular reference to acute otitis media. Am J Med 1990; 88: 15S-9S.
4. Palmu A, Herva E, Savolainen H et al. Association of clinical signs and symptoms with bacterial findings in acute otitis media. Clin Infect Dis 2004; 38: 234-42.
5. Verduin CM, Hol C, Fleer A et al. Moraxella catarrhalis: from emerging to established pathogen. Clin Microbiol Rev 2002; 15: 125-44.
6. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344: 403-9.
7. Revai K, McCormick DP, Patel J et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics 2006; 117: 1823-9.
8. UpToDateOnline. Acute Otitis Media in Children: Treatment. 2010; 17.3. http://www.utdol.com/online/content/topic.do?topicKey=pedi_id/10593& selectedTitle=5%7E150&source=search_result (9 June 2010, date last accessed).
9. Gilbert DN, Moellering RC Jr, Eliopoulos GM et al. The Sanford Guide to Antimicrobial Therapy 2009. Sperryville, USA: Antimicrobial Therapy, Inc. 2009; 212.
10. Dowell SF, Butler JC, Giebink GS et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance- a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999; 18:1-9.
11. Pelton SI, Leibovitz E. Recent advances in otitis media. Pediatr Infect Dis J 2009; 28: S133-7.
12. Al-Shawwa BA, Wegner D. Trimethoprim-sulfamethoxazole plus topical antibiotics as therapy for acute otitis media with otorrhea caused by community-acquired methicillin-resistant Staphylococcus aureus in children. Arch Otolaryngol Head Neck Surg 2005; 131: 782-4.
13. Santos F, Mankarious LA, Eavey RD. Methicillin-resistant Staphylococcus aureus: pediatric otitis. Arch Otolaryngol Head Neck Surg 2000; 126: 1383-5.
14. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007; 298: 1772-8.
15. Leibovitz E, Broides A, Greenberg D et al. Current management of pediatric acute otitis media. Expert Rev Anti Infect Ther 2010; 8: 151-61.
16. Khan MA, Northwood JB, Levy F et al. bro β-lactamase and antibiotic resistances in a global cross-sectional study of Moraxella catarrhalis from children and adults. J Antimicrob Chemother 2010; 65:91-7.
17. Wallace RJ, Steingrube VA, Nash DR et al. BRO β-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal β-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata. Antimicrob Agents Chemotherapy 1989; 33: 1845-54.
18. Eliasson I, Kamme C, Prellner K. b-Lactamase production in the upper respiratory tract flora. Eur J Clin Microbiol 1986; 5: 507-12.
19. Bootsma HJ, van Dijk H, Verhoef J et al. Molecular characterization of the BRO β-lactamase of Moraxella (Branhamella) catarrhalis. Antimicrob Agents Chemother 1996; 40: 966-72.
20. Jetter M, Heiniger N, Spaniol V et al. Outer membrane porin M35 of Moraxella catarrhalis mediates susceptibility to aminopenicillins. BMC Microbiol 2009; 9: 188.
21. Easton DM, Smith A, Gallego SG et al. Characterization of a novel porin protein from Moraxella catarrhalis and identification of an immunodominant surface loop. J Bacteriol 2005; 187: 6528-35.
22. Easton DM, Maier E, Benz R et al. Moraxella catarrhalis M35 is a general porin that is important for growth under nutrient-limiting conditions and in the nasopharynges of mice. J Bacteriol 2008; 190: 7994-8002.
23. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 2003; 67: 593-656.
24. Delcour AH. Solute uptake through general porins. Front Biosci 2003; 8: d1055-71.
25. Schulz GE. The structure of bacterial outer membrane proteins. Biochim Biophys Acta 2002; 1565: 308-17.
26. Pages JM. [Bacterial porin and antibiotic susceptibility]. Med Sci (Paris) 2004; 20: 346-51.
27. Pages JM, James CE, Winterhalter M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol 2008; 6: 893-903.
28. Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta 2009; 1794: 808-16.
29. Hernandez-Alles S, Conejo M, Pascual A et al. Relationship between outer membrane alterations and susceptibility to antimicrobial agents in isogenic strains of Klebsiella pneumoniae. J Antimicrob Chemother 2000; 46: 273-7.
30. Jacoby GA, Mills DM, Chow N. Role of β-lactamases and porins in resistance to ertapenem and other β-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 3203-6.
31. Martinez-Martinez L, Pascual A, Conejo Mdel C et al. Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum β-lactamaseproduction. Antimicrob Agents Chemother2002; 46: 3926-32.
32. Bornet C, Saint N, Fetnaci L et al. Omp35, a new Enterobacter aerogenes porin involved in selective susceptibility to cephalosporins. Antimicrob Agents Chemother 2004; 48: 2153-8.
33. Charrel RN, Pages JM, De Micco P et al. Prevalence of outer membrane porin alteration in β-lactam-antibiotic-resistant Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.
34. Domenech-Sanchez A, Martinez-Martinez L, Hernandez-Alles S et al. Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother 2003; 47: 3332-5.
35. Raja SB, Murali MR, Devaraj SN. Differential expression of ompC and ompF in multidrug-resistant Shigella dysenteriae and Shigella flexneri by aqueous extract of Aegle marmelos, altering its susceptibility toward β-lactam antibiotics. Diagn Microbiol Infect Dis 2008; 61: 321-8.
36. Crowley B, Benedi VJ, Domenech-Sanchez A. Expression of SHV-2 β-lactamase and of reduced amounts of OmpK36 porin in Klebsiella pneumoniae results in increased resistance to cephalosporins and carbapenems. Antimicrob Agents Chemother 2002; 46: 3679-82.
37. Lee K, Yong D, Choi YS et al. Reduced imipenem susceptibility in Klebsiella pneumoniae clinical isolates with plasmid-mediated CMY-2 and DHA-1 β-lactamases co-mediated by porin loss. Int J Antimicrob Agents 2007; 29: 201-6.
38. Hutsul JA, Worobec E. Molecular characterization of the Serratia marcescens OmpF porin, and analysis of S. marcescens OmpF and OmpC osmoregulation. Microbiology 1997; 143: 2797-806.
39. Giuliodori AM, Gualerzi CO, Soto S et al. Review on bacterial stress topics. Ann N Y Acad Sci 2007; 1113: 95-104.
40. Pratt LA, Hsing W, Gibson KE et al. From acids to osmZ: multiple factors influence synthesis of the OmpF and OmpC porins in Escherichia coli. Mol Microbiol 1996; 20: 911-7.
41. Allen KJ, Lepp D, McKellar RC et al. Examination of stress and virulence gene expression in Escherichia coli O157:H7 using targeted microarray analysis. Foodborne Pathog Dis 2008; 5: 437-47.
42. Begic S, Worobec EA. Regulation of Serratia marcescens ompF and ompC porin genes in response to osmotic stress, salicylate, temperature and pH. Microbiology 2006; 152: 485-91.
43. Hanahan D. Studies on transformation of Escherichia coli with plasmids. J Mol Biol 1983; 166: 557-80.
44. Helminen ME, Maciver I, Paris M et al. A mutation affecting expression of a major outer membrane protein of Moraxella catarrhalis alters serum resistance and survival in vivo. J Infect Dis 1993; 168: 1194-201.
45. Heiniger N, Troller R, Meier PS et al. Cold shock response of the UspA1 outer membrane adhesin of Moraxella catarrhalis. Infect Immun 2005; 73: 8247-55.
46. Heiniger N, Spaniol V, Troller R et al. A reservoir of Moraxella catarrhalis in human pharyngeal lymphoid tissue. J Infect Dis 2007; 196: 1080-7.
47. Murphy TF, Loeb MR. Isolation of the outer membrane of Branhamella catarrhalis. Microb Pathog 1989; 6: 159-74.
48. Spaniol V, Troller R, Aebi C. Physiologic cold shock increases adherence of Moraxella catarrhalis to and secretion of interleukin 8 in human upper respiratory tract epithelial cells. J Infect Dis 2009; 200: 1593-601.
49. Davin-Regli A, Bolla JM, James CE et al. Membrane permeability and regulation of drug 'influx and efflux' in enterobacterial pathogens. Curr Drug Targets 2008; 9: 750-9.
50. Malmvall BE, Brorsson JE, Johnsson J. In vitro sensitivity to penicillin V and β-lactamase production of Branhamella catarrhalis. J Antimicrob Chemother 1977; 3: 374-5.
51. Sader HS, Jones RN, Dowzicky MJ et al. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52: 203-8.
52. Johnson DM, Sader HS, Fritsche TR et al. Susceptibility trends of Haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003; 47: 373-6.
53. Deshpande LM, Sader HS, Fritsche TR et al. Contemporary prevalence of BRO β-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004). J Clin Microbiol 2006; 44: 3775-7.
54. Morrissey I, Maher K, Williams L et al. Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007. J Antimicrob Chemother 2008; 62(Suppl 2): ii97-103.
55. Nikaido H. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33: 1831-6.
56. Bornet C, Davin-Regli A, Bosi C et al. Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J Clin Microbiol 2000; 38: 1048-52.
57. Thiolas A, Bornet C, Davin-Regli A et al. Resistance to imipenem, cefepime, and cefpirome associated with mutation in Omp36 osmoporin of Enterobacter aerogenes. Biochem Biophys Res Commun 2004; 317: 851-6.
58. Hernandez-Alles S, Alberti S, Alvarez D et al. Porin expression in clinical isolates of Klebsiella pneumoniae. Microbiology 1999; 145: 673-9.
59. Martinez-Martinez L, Hernandez-Alles S, Alberti S et al. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum- cephalosporins. Antimicrob Agents Chemother 1996; 40: 342-8.
60. Martinez-Martinez L, Pascual A, Hernandez-Alles S et al. Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother 1999; 43: 1669-73.
61. Bradford PA, Urban C, Mariano N et al. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997; 41: 563-9.
62. Ardanuy C, Linares J, Dominguez MA et al. Outer membrane profiles of clonally related Klebsiella pneumoniae isolates from clinical samples and activities of cephalosporins and carbapenems. Antimicrob Agents Chemother 1998; 42: 1636-40.
63. Danelon C, Nestorovich EM, Winterhalter M et al. Interaction of zwitterionic penicillins with the OmpF channel facilitates their translocation. Biophys J 2006; 90: 1617-27.
64. Nestorovich EM, Danelon C, Winterhalter M et al. Designed to penetrate: time-resolved interaction of single antibiotic molecules with bacterial pores. Proc Natl Acad Sci USA 2002; 99: 9789-94.
65. Hengge-Aronis R. Recent insights into the general stress response regulatory network in Escherichia coli. J Mol Microbiol Biotechnol 2002; 4: 341-6.
66. Weber MH, Marahiel MA. Bacterial cold shock responses. Sci Prog 2003; 86: 9-75.
67. Anderson KL, Roberts C, Disz T et al. Characterization of the Staphylococcus aureus heat shock, cold shock, stringent, and SOS responses and their effects on log-phase mRNA turnover. J Bacteriol 2006; 188: 6739-56.
68. Rouadi P, Baroody FM, Abbott D et al. A technique to measure the ability of the human nose to warm and humidify air. J Appl Physiol 1999; 87: 400-6.
69. Gutmann L, Williamson R, Moreau N et al. Cross-resistance to nalidixic acid, trimethoprim, and chloramphenicol associated with alterations in outer membrane proteins of Klebsiella, Enterobacter, and Serratia. J Infect Dis 1985; 151: 501-7.
70. Sanders CC, Sanders WE Jr. β-Lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992; 15: 824-39.
71. Helminen ME, Maciver I, Latimer JL et al. A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model. Infect Immun 1993; 61: 2003-10.
72. Stutzmann Meier P, Heiniger N, Troller R et al. Salivary antibodies directed against outer membrane proteins of Moraxella catarrhalis in healthy adults. Infect Immun 2003; 71: 6793-8.
73. Meier PS, Troller R, Heiniger N et al. Moraxella catarrhalis strains with reduced expression of the UspA outer membrane proteins belong to a distinct subpopulation. Vaccine 2005; 23: 2000-8.
74. Sambrook J, Fritsch E, Maniatis T. Molecular Cloning: a Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.